Kwidabi elichasene nomhlaza wepancreatic, amalingo onyango amatsha kunye nentsha sele ibaluleke kakhulu. Olu lingo lunika izigulane ukufikelela kwangethuba kunyango lwe-Cutting-Edge olunokukhokelela kwinkqubela phambili kuphando kunye nethemba leziphumo ezingcono.
Lonke unyango olukhoyo namhlanje lwaluphandiwe ekuqaleni, lwaphuhliswa kwaye lwamkelwa ngolingo lwezonyango-uphononongo lophando oluphanda ngonyango olutsha okanye indibaniselwano yonyango olukhoyo ukufumanisa ukuba luluncedo na kubantu abaphila nomhlaza wepancreatic. Umhlaza wePancreatic uye usiba yinkxalabo enkulu kwihlabathi jikelele, uhlala uqhuba imfuno yonyango olutsha kunye neenzame zophuhliso lwamachiza. Iimfuno ezingafezekiyo ezinxulumene nesi sifo zitsala iinkampani ezininzi zamazwe ngamazwe ukuba zityale imali kwishishini. Ezi zinto zidityaniswe nokunyuka kwenkcitho yokhathalelo lwempilo kwihlabathi liphela ziya kwandisa ukukhula kwemarike. Ingxelo evela kwi-Global Market Insight yathi ubungakanani beMarike yePancreatic Cancer Treatment kulindeleke ukuba yenze ingeniso enkulu ngo-2021 ukuya ku-2027. Le ngxelo iqhubekile yathi: “Umhlaza wePancreatic uthathwa njengolona hlobo lomhlaza lunamandla olusuka kwizihlunu zepancreatic kwaye lunokukhawulezisa. ukwanda kumalungu akufuphi. Indlela yokuphila engafanelekanga efana nokutshaya, ukusela utywala kunye nokusela icuba kunye nezifo ezinxulumene nendlela yokuphila efana nokutyeba nesifo seswekile ziphakathi koonobangela abaphambili bomhlaza wepancreatic. I-American Cancer Society iqikelela ukuba ngaphezu kwama-60,000 abantu baseMelika abaza kufunyaniswa benomhlaza wepancreatic ngo-2021. Iziganeko ezifanayo ziyabonwa nakwamanye amazwe amaninzi ehlabathini nto leyo eya kuthi ngokuqinisekileyo ixhase ushishino. Iinkampani ezisebenzayo ze-biotech kunye ne-pharma kwiimarike kule veki ziquka i-Oncolytics Biotech® Inc., i-Bristol Myers Squibb, i-Seagen Inc., i-Exact Sciences Corp., i-Kura Oncology, Inc.
I-Global Market Insight yongeze: "I-Chemotherapy, i-immunotherapy, unyango olujoliswe kuyo, kunye nonyango lwehomoni, phakathi kwezinye, ziintlobo ezahlukeneyo zonyango lomhlaza wepancreatic. Phakathi kwezi, icandelo lonyango ekujoliswe kulo linokuthi libambe isabelo esifanelekileyo sentengiso ngo-2027. Unyango ekujoliswe kulo lujolise kwiiproteni ezithile zomhlaza, ufuzo, okanye izicubu ezinegalelo ekukhuleni komhlaza. Unyango luthintela ukukhula kunye nokusasazeka kweeseli zomhlaza ngelixa unciphisa umonakalo kwezo zisempilweni. Unyango ekujoliswe kulo luya kubona ukwanda kwemfuno yonyango lomhlaza wepancreatic kwiminyaka ezayo. ”
I-Oncolytics Biotech® ibonelela ngoHlaziyo oluLungileyo loKhuseleko kwi-Pancreatic Cancer Cohort ye-Multi-Indication Phase 1/2 yeSilingo soMhlaza weGastrointestinal - i-Oncolytics Biotech® ) namhlanje ibhengeze ukugqitywa ngempumelelo kokhuseleko lwezigulana ezintathu ezibalekayo kwi-pancreatic cancer cohort. isigaba 1/2 sophononongo lweGOBLET lulandela uphononongo olwenziwe yiBhodi yokuJonga uKhuseleko lweDatha yophononongo (DSMB). I-DSMB ayizange iphawule iinkxalabo zokhuseleko kwezi zigulana kwaye icebise ukuba isifundo siqhubeke njengoko kucwangcisiwe. Inkqubo yokhuseleko yovavanyo lweqela lesithathu lomhlaza we-metastatic colorectal isaqhuba.
Uphononongo lwe-GOBLET lulawulwa yi-AIO, iqela elikhokelayo kwizifundo ze-oncology yezonyango elizinze eJamani, kwaye yenzelwe ukuvavanya ukhuseleko kunye nokusebenza kakuhle kwe-pelareorep ngokudibanisa ne-Roche's anti-PD-L1 checkpoint inhibitor atezolizumab kwizigulana ezine-metastatic pancreatic, metastatic. colorectal, kunye nomhlaza ezimpundu eziphambili. Uphononongo luhlala luqhuba kwaye kulindeleke ukuba lubhalise izigulane kwiindawo ezili-14 zovavanyo lweklinikhi kulo lonke elaseJamani.
Uphononongo lwe-GOBLET lwe-pancreatic cancer cohort lwandisa idatha yeklinikhi exelwe ngaphambili ebonisa i-synergy kunye nomsebenzi wokuchasana nomhlaza we-pelareorep kudityaniswe nothintelo lwendawo yokuhlola kwizigulane ezinomhlaza we-pancreatic eziqhubele phambili emva konyango lodidi lokuqala (ikhonkco kwi-PR, ikhonkco kwipowusta). Ikwakha kwakhona kwiinkcukacha zeklinikhi zangaphambili ezibonisa ukwanda okukhulu kwe-80% kwi-midian progression-free survival kwizigulane zomhlaza we-pancreatic ezinamazinga aphantsi e-CEACAM6 abonakalisa i-pelareorep ngokudibanisa ne-chemotherapy (ikhonkco kwi-PR, ikhonkco kwipowusta). Ukongeza kokuvavanya ukhuseleko kunye nokusebenza kakuhle kwe-pelareorep-atezolizumab unyango, i-GOBLET iphinda ifune ukubonisa amandla e-CEACAM6 kunye ne-T cell clonality njengezinto eziqikelelwayo ze-biomarkers, ezinokwandisa amathuba okuphumelela kwizifundo zokubhalisa ezizayo ngokuvumela ukhetho lwezona zigulane ezifanelekileyo. .
I-Seagen Inc. isanda kwazisa idatha evela kwisigaba soku-1 solingo lwezonyango oludibanisa i-SEA-CD40 kunye ne-chemotherapy kunye ne-anti-PD-1 kwizigulane ezine-metastatic PDAC kwintlanganiso yonyaka ye-ASCO GI eyenzeka eSan Francisco, ngoJanuwari 20 - 22, 2022. SEA -CD40 iyiveli, uphando, i-nonfucosylated monoclonal receptor-agonistic antibody ejoliswe kwi-CD40, echazwe kwiiseli ze-antigen-presenting. Kwiimodeli zangaphambi kweklinikhi, indibaniselwano ye-SEA-CD40 kunye ne-chemotherapy ibangele umsebenzi we-antitumor oye wandiswa ngakumbi ngonyango lwe-anti-PD-1.
Kwilingo eliqhubekayo lesigaba se-1, i-SEA-CD40 idibaniswe ne-chemotherapy [gemcitabine kunye ne-nab-paclitaxel (GnP)], kunye ne-anti-PD-1 (pembrolizumab), kwizigulane ze-61 ezine-PDAC engaphathwanga ye-metastatic. Kuzo, izigulane ze-40 zafumana i-10 mcg / kg kwaye izigulane ze-21 zafumana i-30 mcg / kg ye-SEA-CD40. Iziphelo eziphambili zibandakanya izinga lokuphendula eliqinisekisiweyo (cORR) nge-RECIST v1.1 ngumphandi, ukusinda okungenasiphelo (PFS) kunye nokusinda ngokubanzi (OS) "Umsebenzi wokuqala uyakhuthaza ngokusekelwe kwiziphumo zembali yechemotherapy. Ukulandelela okungaphezulu kokusinda kuyafuneka ukwazisa amanyathelo ethu alandelayo kumhlaza wepancreatic, ”utshilo uRoger Dansey, MD, iGosa eliyiNtloko lezoNyango eSeagen. "Siyaqhubeka nokuqhubela phambili ulingo oluqhubekayo lwesigaba se-2 se-SEA-CD40 kwi-melanoma kunye nomhlaza wemiphunga ongeyonxalenye encinci."
I-Exact Sciences Corp. kutshanje ibhengeze idatha yokusebenza kwisizukulwana sesibini se-Cologuard (i-multi-target stool DNA) uvavanyo olubonisa uvakalelo olupheleleyo lwe-95.2% yomhlaza we-colorectal (CRC) kwi-specially ye-92.4% yeesampuli ezingalunganga eziqinisekiswe yi-colonoscopy. Uhlalutyo lweqela elingaphantsi lubonise i-83.3% yobuntununtunu kwi-high-grade dysplasia, izilonda ezinobungozi ze-precancerous, kunye ne-57.2% yazo zonke izilonda eziphambili ze-precancerous. Ezi datha ziya kuboniswa nge-22 kaJanuwari kwi-ASCO GI kwipowusta enesihloko esithi, "Iqela lesibini le-Stool ye-DNA yePaneli ngokuthembekileyo ifumanisa uMhlaza weColorectal kunye ne-Advanced Precancerous Lesions."
I-Cologuard lolokuqala noluvunyiweyo yi-FDA kuphela, uvavanyo lwe-DNA lwesitulo esingahlaseli lusetyenziselwa ukuhluza abantu abasemngciphekweni ophakathi kwi-CRC. IiNzululwazi ezichanekileyo ziphuhlisa isizukulwana sesibini i-Cologuard ukuphucula ukucaca kunye novelwano lwe-precancer yovavanyo, ukunciphisa izinga lobuxoki kunye nokunyusa izinga lokubona izilonda ezinobungozi. Uphononongo lubonisa amandla ephaneli yocalucalulo oluphezulu lweempawu ze-DNA ze-methylated kunye ne-fecal hemoglobin ukufeza zombini kwindawo yehlabathi lokwenyani. Ukuba ivunyiwe, uvavanyo lwesizukulwana sesibini lwe-Cologuard lunokunceda ukwandisa amazinga okuhlolwa ngelixa uthumela abantu abambalwa ukuba balandele iikholonoscopies ngokungeyomfuneko kwaye bachonge abaphambili abaphambili ngaphambi kokuba baqhubele phambili kumhlaza, ukunceda ukukhusela isifo.
UBristol Myers Squibb kutshanje ubhengeze iKomiti yeeMveliso zoNyango loSetyenziso loLuntu (CHMP) ye-Arhente yaMayeza yaseYurophu (EMA) iphakamise imvume yeBreyanzi (lisocabtagene maraleucel; liso-cel), iCD19-directed chimeric antigen receptor (CAR) T cell. Unyango lonyango lwezigulane ezikhulileyo ezine-relapsed okanye i-refractory (R / R) zisasaza i-B-cell lymphoma enkulu (DLBCL), i-mediastinal enkulu ye-B-cell lymphoma (PMBCL), kunye ne-follicular lymphoma grade 3B (FL3B) emva kwemigca emibini okanye ngaphezulu. yonyango lwenkqubo. Isiphakamiso se-CHMP ngoku siya kuhlaziywa yiKhomishini yaseYurophu (EC), enegunya lokuvuma amayeza kwi-European Union (EU).
I-Kura Oncology, Inc., inkampani yekliniki ye-biopharmaceutical ezinikele ekufezekiseni isithembiso samayeza achanekileyo kunyango lomhlaza, kutshanje ibhengeze ukuba i-US Food and Drug Administration (FDA) iphakamise ukubanjwa kweklinikhi kwisigaba se-KOMET-001. Uphononongo lwe-1b lwe-KO-539 kwizigulane ezine-leukemia ye-myeloid acute okanye i-refractory acute myeloid (AML). Ukubanjwa kweklinikhi ngokuyinxenye kuye kwaphakanyiswa emva kwesivumelwano ne-FDA malunga neqhinga lokunciphisa leNkampani kwi-syndrome yokwahlukana, isiganeko esibi esaziwayo esinxulumene nee-arhente zokwahlula kunyango lwe-AML.
